Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma

Basudev Chowdhury(Purdue University West Lafayette), Ellen Weisberg(Dana-Farber Cancer Institute)

Cancers

March 28, 2024

10.3390/cancers16071319

Cited by 8

Related Papers

Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7

|Cell chemical biology|2017|188

PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma

|PLoS ONE|2016|96

Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells

|PLoS ONE|2011|47

Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells

|PLoS ONE|2013|42

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells

|Blood|2008|31